o	New preclinical data indicates effect on all major components of immune system
involved in autoimmune diseases
o	Data presented at the 8th Antigen-Specific Immune Tolerance Drug Development
Summit (ASIT) in Boston

Oslo, Norway, February 27, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced new preclinical findings
reinforcing the unique mechanism of action and potential of its APC-targeted
immune therapy platform in treating autoimmune diseases.

Important new data show that Nykode's APC-targeted constructs increase
antigen-specific regulatory T cells, which are known to downregulate an unwanted
immune response, while simultaneously reducing antigen-specific effector T cells
that drive inflammation. Furthermore, new data show that Nykode's APC-targeted
constructs can reduce the generation of antigen-specific IgG autoantibodies,
thereby shaping also the humoral component of the immune response, which is
known to be involved in many autoimmune conditions. These changes suggest that
the therapy works effectively through multiple arms of the antigen-specific
immune system to promote its effectiveness and support its potential as a future
therapy for autoimmune disorders, allergy and organ transplant rejection.

Furthermore, new data show that Nykode's APC-targeting unit is essential for the
observed increased effect in alleviating disease symptoms across preclinical
autoimmune models, demonstrating the versatility and efficacy of the platform.

"These novel data deepen our confidence in the underlying mechanisms of our
APC-targeted therapy platform and its potential in treating conditions caused by
an unwanted immune response, such as autoimmune diseases," said Agnete
Fredriksen, Chief Scientific Officer and Co-founder of Nykode. "We are
encouraged by the ability to measure the  effect through multiple arms of the
immune system, which reinforces our opportunity to build on the strength and
diversity of our unique APC-technology to drive highly specific and customized
immune tolerance."

Most of the data have been generated using MOG and PLP-1 antigens, which are
applicable in chronic and relapsing-remitting EAE models. 

Nykode remains committed to advancing its immune tolerance platform and further
exploring the clinical potential of APC-targeted therapy for autoimmune
diseases, allergies, and organ transplant rejection.

The poster and presentation are available on the Nykode website at
https://nykode.com/research-and-development/scientific-papers-and-presentations.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of cervical
cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, is being
investigated in a trial with more than 10 different indications. 

The Company's partnerships include a multi-target collaboration with Regeneron
in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway